Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias

European Journal of Neurology

Volumn 16, Issue 8, 2009, Pages 895-901

  Bachmann, C G ^a,b   Zapf, A ^a   Brunner, E ^a   Trenkwalder, C ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b PARACELSUS ELENA KLINIK   (Germany)

Author keywords

Body weight; Levodopa; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; BUDIPINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIHYDROERGOCRYPTINE; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; NEUROLEPTIC AGENT; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; ROPINIROLE; SELEGILINE;

ARTICLE; BODY MASS; BODY WEIGHT; DISEASE DURATION; DOPAMINE RELEASE; DYSKINESIA; FOLLOW UP; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; WEIGHT REDUCTION;

AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; BODY MASS INDEX; BODY WEIGHT; DOPAMINE AGENTS; DYSKINESIAS; EATING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; WEIGHT LOSS;

EID: 67651240301     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02617.x     Document Type: Article

References (25)

1. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson's disease. Mov Disord 2006 21 : 1824 1830.
2. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Weight loss in Parkinson's disease. Ann Neurol 2003 53 : 676 679.
3. Markus HS, Tomkins AM, Stern GM. Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect 1993 5 : 117 125.
4. Barichella M, Marczewska A, Vairo A, Canesi M, Pezzoli G. Is underweightness still a major problem in Parkinson's disease patients? Eur J Clin Nutr 2003 57 : 543 547.
5. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology 2006 67 : 1955 1959.
6. Sossi V, de la Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006 129 : 1050 1058.
7. Levi S, Cox M, Lugon M, Hodkinson M, Tomkins A. Increased energy expenditure in Parkinson's disease. Br Med J 1990 301 : 1256 1257.
8. Markus HS, Cox M, Tomkins AM. Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity. Clin Sci (London, England) 1992 83 : 199 204.
9. Toth MJ, Fishman PS, Poehlman ET. Free-living daily energy expenditure in patients with Parkinson's disease. Neurology 1997 48 : 88 91.
10. Jutta Steidl. Mikrozensus 2003. Bonn : Statistisches Bundesamt, 2004.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992 55 : 181 184.
12. Durrieu G, LLau ME, Rascol O, Senard JM, Rascol A, Montastruc JL. Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment. Clin Auton Res 1992 2 : 153 157.
13. Linazasoro G. New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005 26 : 391 397.
14. Uc EY, Struck LK, Rodnitzky RL, Zimmerman B, Dobson J, Evans WJ. Predictors of weight loss in Parkinson's disease. Mov Disord 2006 21 : 930 936.
15. Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003 9 : S73 S81.
16. Oertel WH, Schulz J. Parkinson syndrome. In : Brandt T, Dichgans J, Diener HC, eds. Therapie und Verlauf neurologischer Erkrankungen. Stuttgart : Kohlhammer-Verlag, 2003 : 847 880.
17. Mensink GB, Lampert T, Bergmann E. Overweight and obesity in Germany 1984-2003. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005 48 : 1348 1356.
18. Lampert T, Mensink GB, Ziese T. Sport and health among adults in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005 48 : 1357 1364.
19. Palhagen S, Lorefalt B, Carlsson M, et al. Does l-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? Acta Neurol Scand 2005 111 : 12 20.
20. Zappia M, Crescibene L, Arabia G, et al. Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 2002 25 : 79 82. (Pubitemid 34411825)
21. Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinsonism Relat Disord 2006 12 : 499 505.
22. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesias: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008 15 : 493 496.
23. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006 21 : 524 529.
24. Sharma JC, Ross IN. Long-term role of pergolide as an adjunct therapy in Parkinson's disease: influence on disability, blood pressure, weight and levodopa syndrome. Parkinsonism Relat Disord 1999 5 : 111 114.
25. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003 64 : 22 29.